WO1999047531A1 - Chiral separations of pyrimidines - Google Patents
Chiral separations of pyrimidines Download PDFInfo
- Publication number
- WO1999047531A1 WO1999047531A1 PCT/US1998/005121 US9805121W WO9947531A1 WO 1999047531 A1 WO1999047531 A1 WO 1999047531A1 US 9805121 W US9805121 W US 9805121W WO 9947531 A1 WO9947531 A1 WO 9947531A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chiral
- polar solvent
- lower alkanol
- mixture
- groups
- Prior art date
Links
- 0 Cc1c2nc[n](C)c2nc(*)n1 Chemical compound Cc1c2nc[n](C)c2nc(*)n1 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Definitions
- the present invention relates to the separation of chiral materials utilizing high performance liquid chromatography (HPLC) techniques.
- the present invention pertains to a method of separating an enantiomeric mixture of chiral pyrimidines, or a salt thereof, into their respective enantiomers.
- This method comprises subjecting the chiral mixture to chromatography on chiral polysaccharide stationary phase, eluting with a polar mobile phase, preferably a liquid lower alkanol.
- Pyrimidines constitute an important class of biologically active compounds, encompassing monocyclic nucleic acid bases such as uracil, cytosine, thymine, and 5- methylcytosine, bicyclopyrimidines such as the purine bases adenine, guanine, xanthine, and hypoxanthine, folates and folic acid antagonists, etc. Numerous compounds of this type have been synthesized as antiviral and anticancer drugs. Typical pyrimidine structures include for example:
- Al 0 so include ⁇ d arex the hy>droge Q nated fo O rms of th 0 e forego 0 ing struc 0 tures.
- enantiomers Often the final compounds containing such ring systems will be substituted with a chiral group, thereby giving rise to the existence of enantiomers, and in such cases it generally is desirable to separate the enantiomers into chirally pure form.
- iodoxuridine, vidarabine, azidothymidine, sparsomycin, cytosine arabinoside, 5-fluorouridine, methotrexate, DDATHF, and aminopterin are biologically active pyrimidine compounds containing a center of chirality.
- enantiomeric separations encompassed by the present invention utilize chiral polysaccharides as stationary phases.
- chiral polysaccharides as stationary phases.
- aromatic carbamate or ester derivatives of cellulose or amylose which can be generically represented by the formula:
- glucosidic linkage is either (amylose) or ⁇ (cellulose).
- R groups can be for example a phenylcarbamate or ⁇ -phenethylcarba- mate. which itself is chiral, or a benzoate group.
- Typical R groups thus include 3,5- dimethylphenyl carbamate, ⁇ -phenethylcarbamate, and 4- methylbenzoate, e.g. :
- Such chiral polysaccharide stationary supports are commercially available from Chiral Technologies, Inc., Exton, PA, under the trademarks CHIRALPAK ® amylosic stationary phase and CHIRALCEL cellulosic stationary phase.
- Suitable materials include CHIRALPAK AD , an amylose derivative in which each glucose monomer carries three 3,5-dimethylphenyl carbamate groups, CHIRALPAK" AS , an amylose derivative in which each glucose monomer carries three (S)- -phenethylcarbamate groups, CHIRALCEL OD , a cellulose derivative in which each glucose monomer carries three 3.5-dimethylphenyl carbamate groups, and CHIRALCEL OJ , a cellulose derivative in which each glucose monomer carries three 4-methylbenzoyl groups.
- CHIRALPAK AD an amylose derivative in which each glucose monomer carries three 3,5-dimethylphenyl carbamate groups
- CHIRALPAK an amylose derivative
- the stationary phase conveniently can be packed in columns adapted for use with commercially available HPLC systems, as for example those available from 3
- the particle diameter will be from about 1 to about 100 ⁇ m, typically from about 5 to about 75 ⁇ m. Multiple or single columns can be employed.
- a simulated moving bed apparatus also can be employed, as described for example in U.S. Patent Nos. 5,434,298, 5,434,299, 5,456,825, and 5,498,752, the disclosures of which are incorporated herein by reference.
- the eluent or mobile phase comprises a liquid polar solvents such as methanol, ethanol, n-propanol, isopropanol, butanol, acetonitrile, supercritical carbon dioxide and the like, preferably acetonitrile or a liquid lower alkanol such as ethanol or methanol. Also of value is supercritical carbon dioxide, alone or in combination with at one or more of acetonitrile and a liquid lower alkanol.
- a liquid polar solvents such as methanol, ethanol, n-propanol, isopropanol, butanol, acetonitrile, supercritical carbon dioxide and the like, preferably acetonitrile or a liquid lower alkanol such as ethanol or methanol.
- supercritical carbon dioxide alone or in combination with at one or more of acetonitrile and a liquid lower alkanol.
- the separation will be conducted at ambient temperatures; e.g., 25-40°C. pH will vary depending upon the nature of the material being chromatographed but generally will be from about 2 to about 7. Typical flow rates are from about 0.2 mL/min. to about 25 mL/min., depending on the apparatus, column dimensions, and stationary phase.
- Separation can be monitored by measuring UV absorption, optical rotation, refractive index, evaporative light scattering, or a similar physical parameter. Detection can be conducted for example by measuring UN absorption at an appropriate wavelength of the eluted material, utilizing a UN spectrophotometer, or the optical activity of the eluted material, using for example a device such as the IBZ Chiralyser ® instrument (available from JM Science, Inc., Grand Island, ⁇ Y) which monitors the rotation of plane polarized light. The parameter selected for detection will depend on the specific pyrimidine compound being eluted. The following examples will serve to further typify the nature of the invention but should not be construed as limitation on the scope thereof which is defined solely by the appended claims.
- Example 2 was separated into its two enantiomers using the procedure of Example 1. Good separation into two distinct peaks was observed. The first enantiomer eluted was dextrorotatory.
- Example 2 was separated into its two enantiomers using the procedure of Example 1. Good separation into two distinct peaks was observed. The first enantiomer eluted was the dextrorotatory form.
- R is for example t-butyldiphenylsilyloxy
- each of R , R . and R is hydrogen, methyl, chloro, fluoro, trifluoromethyl, or trichloromethyl.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98914244A EP1070076A4 (en) | 1998-03-16 | 1998-03-16 | Chiral separations of pyrimidines |
AU68647/98A AU6864798A (en) | 1998-03-16 | 1998-03-16 | Chiral separations of pyrimidines |
PCT/US1998/005121 WO1999047531A1 (en) | 1998-03-16 | 1998-03-16 | Chiral separations of pyrimidines |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1998/005121 WO1999047531A1 (en) | 1998-03-16 | 1998-03-16 | Chiral separations of pyrimidines |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999047531A1 true WO1999047531A1 (en) | 1999-09-23 |
Family
ID=22266603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/005121 WO1999047531A1 (en) | 1998-03-16 | 1998-03-16 | Chiral separations of pyrimidines |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1070076A4 (en) |
AU (1) | AU6864798A (en) |
WO (1) | WO1999047531A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002001223A1 (en) * | 2000-06-28 | 2002-01-03 | Mip Technologies Ab | Substructure approach to molecularly imprinted polymers with high selectivity for folic acid and analogues |
EP1712905A1 (en) * | 2004-02-03 | 2006-10-18 | Daicel Chemical Industries, Ltd. | Method of optical isomer separation with use of supercritical fluid chromatography |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4861872A (en) * | 1986-03-20 | 1989-08-29 | Daicel Chemical Industries, Ltd. | Alkyl-phenylcarbamate derivative of polysaccharide |
US4912205A (en) * | 1986-03-20 | 1990-03-27 | Daicel Chemical Industries, Ltd. | Alkyl-substituted phenylcarbamate derivative of polysaccharide |
US5196575A (en) * | 1992-02-19 | 1993-03-23 | Hoechst Celanese Corp. | Supercritical separation of isomers of functional organic compounds at moderate conditions |
US5202433A (en) * | 1989-07-27 | 1993-04-13 | Daicel Chemical Industries, Ltd. | Polysaccharide derivatives as separating agents |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3010816B2 (en) * | 1991-08-22 | 2000-02-21 | ダイセル化学工業株式会社 | Method for recovering optical isomer and solvent in optical resolution, method for recycling solvent, and method for reusing optical isomer |
-
1998
- 1998-03-16 EP EP98914244A patent/EP1070076A4/en not_active Withdrawn
- 1998-03-16 AU AU68647/98A patent/AU6864798A/en not_active Abandoned
- 1998-03-16 WO PCT/US1998/005121 patent/WO1999047531A1/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4861872A (en) * | 1986-03-20 | 1989-08-29 | Daicel Chemical Industries, Ltd. | Alkyl-phenylcarbamate derivative of polysaccharide |
US4912205A (en) * | 1986-03-20 | 1990-03-27 | Daicel Chemical Industries, Ltd. | Alkyl-substituted phenylcarbamate derivative of polysaccharide |
US5202433A (en) * | 1989-07-27 | 1993-04-13 | Daicel Chemical Industries, Ltd. | Polysaccharide derivatives as separating agents |
US5196575A (en) * | 1992-02-19 | 1993-03-23 | Hoechst Celanese Corp. | Supercritical separation of isomers of functional organic compounds at moderate conditions |
Non-Patent Citations (1)
Title |
---|
See also references of EP1070076A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002001223A1 (en) * | 2000-06-28 | 2002-01-03 | Mip Technologies Ab | Substructure approach to molecularly imprinted polymers with high selectivity for folic acid and analogues |
EP1712905A1 (en) * | 2004-02-03 | 2006-10-18 | Daicel Chemical Industries, Ltd. | Method of optical isomer separation with use of supercritical fluid chromatography |
EP1712905A4 (en) * | 2004-02-03 | 2008-04-09 | Daicel Chem | Method of optical isomer separation with use of supercritical fluid chromatography |
Also Published As
Publication number | Publication date |
---|---|
EP1070076A4 (en) | 2002-05-29 |
EP1070076A1 (en) | 2001-01-24 |
AU6864798A (en) | 1999-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Müller et al. | Synthesis and structure− activity relationships of 3, 7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists | |
Norman et al. | A structure-based library approach to kinase inhibitors | |
CN1946405B (en) | Use of 9h-purine-2,6-diamine derivatives in the treatment of proliferative diseases and novel 9h-purine-2,6-diamine derivatives | |
Kim et al. | Structure− activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions | |
JP2928386B2 (en) | Depression treatment agent | |
JP2012521994A (en) | Atropisomers of 2-prinyl-3-tolyl-quinazolinone derivatives and methods of use | |
CA2521879C (en) | Process for resolving amines that are useful for the treatment of disorders associated with insulin resistance syndrome | |
US20070191380A1 (en) | Kinase inhibitor scaffolds and methods for their preparation | |
WO2006034473A2 (en) | Novel pyrimidine compounds, process for their preparation and compositions containing them | |
Gangjee et al. | 6-Substituted 2, 4-diaminopyrido [3, 2-d] pyrimidine analogues of piritrexim as inhibitors of dihydrofolate reductase from rat liver, Pneumocystis carinii, and Toxoplasma gondii and as antitumor agents | |
Toribio et al. | Study of the enantiomeric separation of an acetamide intermediate by using supercritical fluid chromatography and several polysaccharide based chiral stationary phases | |
US20200262791A1 (en) | Quinoline derivative and use thereof as tyrosine kinase inhibitor | |
Niculescu-Duvaz et al. | Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead | |
Carotti et al. | Design, synthesis, and structure− activity relationships of 1-, 3-, 8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor | |
EP1070076A1 (en) | Chiral separations of pyrimidines | |
Di Lucrezia et al. | Solid phase synthesis of purines from pyrimidines | |
KR100704009B1 (en) | 6-Alkylamino-2-methyl-2'-N-methyl substituted sulfonamidomethyl-2H-1-benzopyran derivatives as anti-inflammatory inhibitors | |
Novellino et al. | Design, synthesis and biological evaluation of novel N-alkyl-and N-acyl-(7-substituted-2-phenylimidazo [1, 2-a][1, 3, 5] triazin-4-yl) amines (ITAs) as novel A1 adenosine receptor antagonists | |
Gangjee et al. | Nonclassical 2, 4-diamino-8-deazafolate analogues as inhibitors of dihydrofolate reductases from rat liver, Pneumocystis carinii, and Toxoplasma gondii | |
RU2596823C2 (en) | DERIVATIVES OF 7-(HETEROARYL-AMINO)-6,7,8,9-TETRAHYDROPYRIDO[1,2-a]INDOLE-ACETIC ACID AND USE THEREOF AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | |
US5866576A (en) | Epoxide-containing compounds | |
CN107118192B (en) | Derivative of dihydromyricetin containing halogen and its preparation method and application | |
Denhart et al. | Diaminopyrimidine and diaminopyridine 5-HT7 ligands | |
Weising et al. | Stereoselective Synthesis of 1′, 2′-cis-Disubstituted Carbocyclic ribo-Nucleoside Analogues | |
Zhang et al. | Synthesis and anti-proliferative activity evaluation of sorafenib derivatives with a 3-arylacryloyl hydrazide unit |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998914244 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998914244 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998914244 Country of ref document: EP |